Gernandt & Danielsson has advised Carnegie Investment Bank and Handelsbanken Capital Markets in connection with the listing of Camurus AB (publ) (“Camurus”) shares on Nasdaq Stockholm.

The offering was priced at SEK 57 per share. The offering consisted of 12,813,937 shares, including an over-allotment option of 1,671,383 shares, corresponding to a total value of the offering of SEK 730 million.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies.
Carnegie Investment Bank and Handelsbanken Capital Markets acted as Joint Global Coordinators and Joint Bookrunners in connection with the offering.
Gernandt & Danielsson advised the Joint Global Coordinators and Joint Bookrunners with a team consisting of Partner Carl Westerberg, Senior Associate Pär Johansson and Associate Aleksander Källkvist.